See more : Arex Industries Limited (AREXMIS.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Delta-Fly Pharma, Inc. (4598.T) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Delta-Fly Pharma, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Hamashbir 365 Ltd (MSBI.TA) Income Statement Analysis – Financial Results
- Lachlan Star Limited (LSLCF) Income Statement Analysis – Financial Results
- Menora Mivtachim Holdings Ltd (MNRHF) Income Statement Analysis – Financial Results
- Equitas Holdings Limited (EQUITAS.NS) Income Statement Analysis – Financial Results
- Vikas Lifecare Limited (VIKASLIFE.NS) Income Statement Analysis – Financial Results
Delta-Fly Pharma, Inc. (4598.T)
About Delta-Fly Pharma, Inc.
Delta-Fly Pharma, Inc. develops anticancer drugs. It develops DFP-10917 that is in phase III clinical trial in the United States and phase I trial in Japan for the treatment of relapsed/refractory acute myeloid leukemia; DFP-14323, which is in phase III clinical trial to treat lung cancer; DFP-17729 that is in phase I/II clinical trials for the treatment of solid cancer; DFP-11207, which has completed phase I clinical trial to treat pancreatic cancer; DFP-14927 that is in phase I for the treatment of hematologic cancer; and DFP-10825, which is in preclinical trial to treat gastric/ovarian cancer. Delta-Fly Pharma, Inc. was incorporated in 2010 and is headquartered in Tokushima, Japan.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 300.00M | 300.00M | 100.00M | 0.00 | 150.00M | 902.05M |
| Cost of Revenue | 1.51M | 1.63M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 46.00K |
| Gross Profit | -1.51M | -1.63M | 300.00M | 300.00M | 100.00M | 0.00 | 150.00M | 902.00M |
| Gross Profit Ratio | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 0.00% | 100.00% | 99.99% |
| Research & Development | 1.12B | 1.01B | 940.79M | 866.92M | 1.40B | 376.94M | 199.34M | 317.21M |
| General & Administrative | 284.85M | 303.98M | 320.68M | 285.31M | 63.00M | 48.00M | 194.47M | 256.17M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 155.00M | 132.00M | 0.00 | 0.00 |
| SG&A | 284.85M | 303.98M | 320.68M | 285.31M | 218.00M | 180.00M | 194.47M | 256.17M |
| Other Expenses | 1.00K | 32.00K | 120.00K | 211.00K | -30.62M | 35.06M | 0.00 | 1.00K |
| Operating Expenses | 1.40B | 1.32B | 1.26B | 1.15B | 1.65B | 592.00M | 393.82M | 573.39M |
| Cost & Expenses | 1.40B | 1.32B | 1.26B | 1.15B | 1.65B | 592.00M | 393.82M | 573.38M |
| Interest Income | 14.00K | 13.00K | 70.00K | 227.00K | 55.00K | 0.00 | 222.00K | 209.00K |
| Interest Expense | 0.00 | 0.00 | 1.88M | 43.00K | 170.00K | 0.00 | 442.00K | 574.00K |
| Depreciation & Amortization | 1.51M | 1.63M | 1.67M | 2.01M | 1.00M | 1.00M | 948.00K | 1.04M |
| EBITDA | -1.40B | -1.32B | -960.00M | -857.32M | -1.55B | -591.00M | -243.12M | 324.90M |
| EBITDA Ratio | 0.00% | 0.00% | -319.93% | -285.77% | -1,544.00% | 0.00% | -162.08% | 36.02% |
| Operating Income | -1.40B | -1.32B | -961.46M | -852.23M | -1.55B | -592.00M | -243.82M | 328.66M |
| Operating Income Ratio | 0.00% | 0.00% | -320.49% | -284.08% | -1,545.00% | 0.00% | -162.55% | 36.44% |
| Total Other Income/Expenses | -23.43M | -9.95M | -2.60M | -7.14M | -6.70M | -79.00M | -687.00K | -5.38M |
| Income Before Tax | -1.43B | -1.33B | -964.06M | -859.37M | -1.55B | -671.00M | -244.51M | 323.29M |
| Income Before Tax Ratio | 0.00% | 0.00% | -321.35% | -286.46% | -1,552.00% | 0.00% | -163.00% | 35.84% |
| Income Tax Expense | 2.50M | 3.03M | 3.24M | 3.21M | 3.00M | 2.00M | 1.76M | 18.18M |
| Net Income | -1.43B | -1.33B | -967.30M | -862.59M | -1.56B | -673.00M | -246.27M | 305.11M |
| Net Income Ratio | 0.00% | 0.00% | -322.43% | -287.53% | -1,555.00% | 0.00% | -164.18% | 33.82% |
| EPS | -198.72 | -234.51 | -178.58 | -187.34 | -348.14 | -169.97 | -92.19 | 70.87 |
| EPS Diluted | -198.72 | -234.51 | -178.58 | -187.34 | -348.14 | -169.97 | -92.19 | 70.87 |
| Weighted Avg Shares Out | 7.19M | 5.67M | 5.42M | 4.60M | 4.47M | 3.96M | 2.67M | 4.31M |
| Weighted Avg Shares Out (Dil) | 7.19M | 5.67M | 5.42M | 4.60M | 4.47M | 3.96M | 2.67M | 4.31M |
Source: https://incomestatements.info
Category: Stock Reports